Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine

Grit Sommer(University of Bern), Mathias Faßhauer(Center for Clinical Research (United States)), Antje Garten(University Hospital Leipzig), Annette G. Beck‐Sickinger(Leipzig University of Applied Sciences), Matthias Blüher(Leipzig University), Michael Stümvoll(IFB Adiposity Diseases), Stefanie Petzold
Clinical Science
June 2, 2008
10.1042/cs20070226
Cited by 161

Related Papers

Definition and diagnostic criteria of clinical obesity
|The Lancet Diabetes & Endocrinology|2025|1.3k
Metabolically Healthy Obesity
|Endocrine Reviews|2020|995
Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
|Cell Metabolism|2007|899
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
|Pharmacological Reviews|1998|893
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843